What Are Peptides for Weight Loss? Definition, Compounded Peptide Landscape + Evidence Review

This evidence review is part of Weight Loss Rankings' living editorial database — 100+ research articles and 158+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Search “peptides for weight loss” and you will find three very different things bundled under the same term: real FDA-approved peptide drugs like Wegovy and Zepbound; compounded versions of those same molecules from 503A pharmacies; and “research peptides” like BPC-157, AOD-9604, and MOTS-c that have no FDA approval for weight loss in any population. The clinical evidence gap between the categories is enormous. This article maps the territory so you know which category you are actually dealing with.

What is a peptide?

A peptide is a short chain of amino acids — the same building blocks that make up proteins. The distinction between a peptide and a protein is largely one of length: peptides typically have fewer than 50 amino acids; proteins are longer chains (though the boundary is not precisely defined). Many hormones are peptides. Insulin, one of the most prescribed drugs in history, is a 51-amino acid peptide. Oxytocin is a 9-amino acid peptide.

Peptides are named and structured by their amino acid sequence. Semaglutide — the active molecule in Wegovy and Ozempic — is a 31-amino acid synthetic analogue of the human GLP-1 hormone.^[9] Tirzepatide — the active molecule in Zepbound and Mounjaro — is a 39-amino acid dual GIP/GLP-1 receptor agonist.^[10] Liraglutide — the active molecule in Saxenda — is a 34-amino acid acylated GLP-1 analogue.^[3]

Why most peptides are injected, not swallowed: Peptides are broken down by stomach acid and digestive enzymes — the same system that digests the protein in food. When you swallow a peptide drug, the GI tract often cleaves the amino-acid bonds before the drug can reach the bloodstream. This is why every FDA-approved injectable GLP-1 drug (Wegovy, Zepbound, Saxenda) is delivered subcutaneously rather than orally.

Rybelsus (oral semaglutide, Novo Nordisk) is the one peptide that survived the formulation challenge: it uses an absorption enhancer called SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) to create a brief absorption window in the stomach under strict fasting conditions — with an absolute bioavailability of roughly 1% and a T2D-only indication. It is not approved for weight management.

Foundayo (orforglipron) sidesteps the problem entirely: it is not a peptide. It is a small-molecule, non-amino-acid GLP-1 receptor agonist that survives digestion without an absorption enhancer. The Foundayo label explicitly does not restrict dosing to a fasted state.^[8] This matters for the “peptides for weight loss” category: Foundayo is the only FDA-approved oral option for chronic weight management as of May 2026 — but it is not a peptide.

The three categories of “weight loss peptides”

The marketing term “peptides for weight loss” groups three structurally different things. Understanding the category is the most important step before evaluating any claim.

The rest of this article covers each category in turn, with verbatim FDA label language for Category 1 and verified regulatory status for Categories 2 and 3.

Category 1: FDA-approved peptide drugs for weight management

The three FDA-approved injectable medications for chronic weight management are all peptide drugs. Their indication sections read as follows on the current DailyMed labels:

Wegovy (semaglutide 2.4 mg) — 31-amino acid peptide

Wegovy (Novo Nordisk, approved June 2021) is a 31-amino acid synthetic GLP-1 receptor agonist. The DailyMed Section 1 indication states verbatim:

“WEGOVY is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).” ^[1]

In the STEP-1 phase 3 trial, semaglutide 2.4 mg weekly produced a mean body-weight reduction of −14.9% at 68 weeks versus −2.4% for placebo (PMID 33567185).^[4] Wegovy is a once-weekly subcutaneous injection.

Zepbound (tirzepatide) — 39-amino acid dual peptide

Zepbound (Eli Lilly, approved November 2023) is a 39-amino acid peptide that simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors — a dual mechanism not present in semaglutide or liraglutide. The DailyMed Section 1 indication states verbatim:

“ZEPBOUND is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea).”^[2]

In the SURMOUNT-1 phase 3 trial, tirzepatide 15 mg weekly produced a mean body-weight reduction of −20.9% at 72 weeks versus −3.1% for placebo (PMID 35658024).^[5] The SURMOUNT-5 head-to-head trial (PMID 40353578) directly compared tirzepatide versus semaglutide 2.4 mg in the same patient population and confirmed tirzepatide produced greater mean weight loss.^[13]

Saxenda (liraglutide 3.0 mg) — 34-amino acid peptide

Saxenda (Novo Nordisk, approved December 2014) is a 34-amino acid acylated GLP-1 analogue. It was the first injectable GLP-1 receptor agonist approved specifically for chronic weight management. The DailyMed Section 1 indication states verbatim:

“SAXENDA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition.” ^[3]

In the SCALE Obesity and Prediabetes phase 3 trial, liraglutide 3.0 mg daily produced a mean body-weight reduction of −8.0% at 56 weeks versus −2.6% for placebo (PMID 26132939).^[6] A first FDA-approved generic (Teva, August 2025) is now available. Saxenda is a once-daily subcutaneous injection.

Foundayo (orforglipron) — FDA-approved for weight management but NOT a peptide

Foundayo (Eli Lilly, approved April 1, 2026) is the first FDA-approved oral medication for chronic weight management in the GLP-1 era. The ATTAIN-1 trial showed mean weight loss of −11.1% / −24.9 lbs at 17.2 mg over 72 weeks.^[8] However, orforglipron is not a peptide. It is a non-peptide small-molecule GLP-1 receptor agonist — meaning it is not built from amino acids. Its structure allows it to bind the GLP-1 receptor and survive oral digestion without an absorption enhancer. When a clinic describes Foundayo as a “peptide,” that is technically incorrect.

Category 2: Compounded peptide versions

Compounded semaglutide and compounded tirzepatide use the same active peptide molecules as Wegovy and Zepbound, respectively. A licensed 503A compounding pharmacy prepares them under a patient-specific prescription from a licensed prescriber. They are not FDA-approved products.

What “not FDA-approved” means in this context

Compounded preparations have not undergone the same FDA manufacturing review, bioequivalence testing, or post-market surveillance that Wegovy and Zepbound underwent. Quality, potency, and sterility depend on the specific compounding pharmacy's practices, equipment, and USP <797> compliance. A compounded semaglutide preparation is not a generic version of Wegovy — the regulatory category is fundamentally different.

Regulatory landscape (May 2026)

The compounded GLP-1 landscape changed materially in early 2025. The FDA issued a declaratory order on February 21, 2025 finding that semaglutide injection was no longer in shortage. Under FDCA sections 503A(b)(1)(D) and 503B(a)(2), the shortage condition that had justified large-scale compounding was removed for 503B outsourcing facilities. A similar resolution applied to tirzepatide in March 2025.

As of May 2026, the regulatory environment remains in transition. Multiple compounding pharmacies have challenged FDA enforcement in federal court. 503A patient-specific compounding continues to be available under appropriate clinical justification (formulation need the brand cannot meet, patient-specific need documented by the prescriber). If you are currently using compounded semaglutide or tirzepatide, ask your pharmacy: under what legal basis are you currently compounding this preparation?

For the complete compounded GLP-1 comparison — dose schedules, storage, additives (B12, NAD+), cost, and regulatory status — see our companion article: compounded tirzepatide vs. compounded semaglutide (2026).

Category 3: Research peptides marketed for weight loss

This category is the source of most of the confusion in the “peptides for weight loss” search space. The compounds below are frequently mentioned in clinic marketing, social media, and online pharmacies under the “peptide therapy” umbrella. None are FDA-approved for weight loss in any population. We cover each with its actual regulatory status.

AOD-9604

AOD-9604 is a modified fragment of the C-terminus of human growth hormone (hGH176-191), designed to activate fat-burning pathways without the growth-promoting effects of full-length hGH. The primary published mechanism evidence is an animal study in obese mice showing increased fat oxidation with chronic treatment (Heffernan MA et al., Int J Obes Relat Metab Disord 2001, PMID 11673763).^[11]

Regulatory status: AOD-9604 has no FDA approval for any human indication. It is not listed in DailyMed. No published Phase 2 or Phase 3 human weight-loss randomized controlled trial appears in PubMed as of May 2026. The FDA's Tainted Weight Loss Products database and Warning Letters database include actions against companies distributing AOD-9604 for human consumption.^[12]

BPC-157 (“Body Protective Compound 157”)

BPC-157 is a synthetic 15-amino acid peptide derived from a partial sequence found in human gastric juice. It appears primarily in the sports-medicine and anti-aging marketing space with claims of tissue healing, gut protection, and cardiovascular benefit. Some sellers include weight management as a claim.

Regulatory status: BPC-157 has no FDA approval for any human indication. It is not listed in DailyMed. No published Phase 2 or Phase 3 human weight-loss randomized controlled trial appears in PubMed as of May 2026. The FDA has issued warning letters to companies distributing BPC-157 for human consumption.^[12] It is sold as a “research peptide” with the explicit disclaimer that it is not for human use — a distinction widely ignored in practice.

Tesamorelin (Egrifta SV / Egrifta WR) — FDA-approved, but not for weight loss

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is FDA-approved — but the approved indication is very specific. The DailyMed Section 1 indication (SetID 3d783378-b02d-4f19-99dd-0fc91a042224) states verbatim:

“EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.” ^[7]

Tesamorelin is not FDA-approved for general weight loss in the non-HIV-infected obese population. Prescribing or marketing it for general weight management is off-label use in an unapproved population. The DailyMed Section 5 warnings note concern about neoplasm risk in patients with active malignancies.^[7] The drug is not compounded; it is only available as brand-name Egrifta SV or Egrifta WR through authorized channels.

The confusion: tesamorelin does reduce abdominal fat, but only in HIV-associated lipodystrophy. Clinics that market it as a peptide for general weight loss or body composition are describing an off-label, unapproved use.

MOTS-c

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a mitochondria-derived peptide identified in the early 2010s. Research interest focuses on its potential role in metabolic regulation, including insulin sensitivity and fat metabolism — primarily in cell and animal models. No Phase 2 or Phase 3 human weight-loss trial appears in PubMed as of May 2026.

Regulatory status: MOTS-c has no FDA approval for any human indication. It is a research-use compound. Human data are limited to early-phase observational and mechanistic work. It is not recommended for weight loss.

GHK-Cu (copper peptide)

GHK-Cu is a tripeptide (glycine-histidine-lysine) with a copper ion. It has been studied primarily as a topical cosmetic/skincare ingredient for skin repair and collagen stimulation. It is marketed in some peptide-therapy settings for body composition, but this use is not supported by human clinical trial data for weight loss.

Regulatory status: GHK-Cu has no FDA approval for any systemic (injectable or oral) indication. It appears as a topical cosmetic ingredient, not a weight-loss drug. It is not listed in DailyMed for any drug indication.

Sermorelin

Sermorelin is a synthetic analogue of GHRH (growth hormone-releasing hormone), similar in mechanism to tesamorelin. It was FDA-approved in the 1990s as Geref Diagnostic for evaluation of growth hormone secretory capacity in children. Sermorelin was withdrawn from the US market by the manufacturer in 2008 and no longer has an FDA-approved product on the market.

Current status: Sermorelin is now available only as a compounded preparation. It has no FDA-approved indication for weight loss. Some compounding pharmacies prepare sermorelin injections as part of anti-aging or “hormone optimization” programs; this use is not FDA-approved and has no Phase 3 weight-loss trial evidence.

Lipotropic injections (B12 + amino acid “MIC” combinations)

Lipotropic injections — typically combinations of vitamin B12 with methionine, inositol, choline (“MIC”), and sometimes L-carnitine or other amino acids — are sometimes marketed as “peptide injections for weight loss.” Technically, they contain individual amino acids or amino acid derivatives, not assembled peptide chains. They have no FDA approval for weight loss. No registration-quality randomized controlled trial demonstrates clinically meaningful weight loss from these combinations.

What “peptide therapy” usually means at telehealth clinics

When a telehealth clinic advertises “peptide therapy for weight loss,” the most likely scenario is that they are prescribing compounded semaglutide (Category 2) or compounded tirzepatide (Category 2) using the umbrella term “peptide therapy” loosely. This framing is technically accurate — semaglutide and tirzepatide are peptides — but it papers over the critical distinction between FDA-approved brand-name drugs, compounded versions of those drugs, and unapproved research peptides.

Less reputable providers use “peptide therapy” as a catch-all that includes Category 3 research peptides alongside compounded GLP-1s. A patient who hears “peptide therapy” may not know whether they are being prescribed something with Phase 3 human evidence or a compound with no approved human indication.

If a provider cannot tell you the specific molecule name — “semaglutide” or “tirzepatide” by name — that is a significant red flag. The prescription in your hands should name a specific active pharmaceutical ingredient.

Safety and regulatory caveats for non-FDA-approved peptides

FDA-approved peptide drugs (Category 1) have extensive safety monitoring: pre-market clinical trials with tens of thousands of patients, post-market surveillance, a defined manufacturing quality standard (cGMP), and a prescriber-monitored dosing structure. They carry known risks that patients and prescribers evaluate together.

Category 3 research peptides — BPC-157, AOD-9604, MOTS-c, GHK-Cu, and compounded sermorelin — present a very different risk profile:

• Minimal human safety data. Most published data come from cell culture and animal models. Human safety at the doses marketed for weight loss has not been established in clinical trials.
• No FDA manufacturing oversight for human use. Research peptides sold online have no requirement to meet FDA Good Manufacturing Practice standards. Purity, potency, and sterility of injectable preparations are not independently verified.
• FDA enforcement history. The FDA has issued warning letters to companies distributing BPC-157, AOD-9604, and TB-500/thymosin beta-4 for human consumption, citing distribution of unapproved new drugs.^[12]
• Unknown interactions. Research peptides have not been tested in combination with GLP-1 drugs, common chronic disease medications, or each other. The interaction profile is unknown.
• Importation risk. Many research peptides sold in the US are manufactured overseas and imported without FDA inspection. Importation of unapproved drugs for personal use is legally complex and carries contamination risk.

The FDA's public-facing Tainted Weight Loss Products database and Warning Letters database are the primary-source references for the enforcement record.^[12] We do not name specific vendors; we encourage anyone evaluating a “peptide therapy” program to search those databases by product name before making a decision.

Efficacy comparison: FDA-approved peptides vs. research peptides

The clinical evidence gap between Category 1 and Category 3 is not close. Here is what the best available evidence shows for each:

Cross-trial caveat: the Zepbound, Wegovy, and Saxenda figures are from separate trials with different populations and cannot be directly compared except via SURMOUNT-5 (tirzepatide vs. semaglutide head-to-head, PMID 40353578). Individual results vary.

What to ask your provider

If you are evaluating a telehealth clinic or weight-loss provider that offers “peptide therapy,” these five questions narrow down which category you are actually dealing with — and whether the program is evidence-based:

1. What is the exact molecule name? Semaglutide, tirzepatide, liraglutide, or something else? If the provider cannot name the active pharmaceutical ingredient by its INN (international nonproprietary name), that is a red flag.
2. Is it FDA-approved? For which indication? Brand Wegovy, Zepbound, and Saxenda are FDA-approved for chronic weight management. Tesamorelin is FDA-approved for HIV lipodystrophy only. Compounded semaglutide and tirzepatide are not FDA-approved products. Research peptides are not approved for any human indication.
3. Is it brand-name, compounded, or a research peptide? If compounded: which 503A pharmacy, what is their NABP number, and are they PCAB-accredited? If a research peptide: what is the FDA regulatory status and where is the human safety data?
4. What is the dose ladder? Legitimate GLP-1 programs follow structured titration that matches or approximates the FDA label dose escalation (e.g., Wegovy starts at 0.25 mg weekly, escalates over 16–20 weeks to 2.4 mg). The absence of a titration schedule is a red flag.
5. What monitoring is included? GLP-1 drugs require ongoing prescriber monitoring. Thyroid history review, contraindication screening, and gastrointestinal side-effect management are not optional steps.

For a ranked, verified list of telehealth providers prescribing FDA-approved semaglutide and tirzepatide programs, see our provider rankings. Every provider in our database has a live-verified verification block with the specific drug, regulatory status, and cost.

Bottom line

• Wegovy (semaglutide, 31aa), Zepbound (tirzepatide, 39aa), and Saxenda (liraglutide, 34aa) are all peptide drugs and all FDA-approved for chronic weight management. They have Phase 3 human trial evidence of −8% to −21% body weight loss.
• Compounded semaglutide and tirzepatide use the same molecules but are not FDA-approved products. Efficacy is extrapolated from brand trials; manufacturing quality varies by pharmacy. The regulatory landscape post-February 2025 is unsettled.
• BPC-157, AOD-9604, MOTS-c, GHK-Cu, compounded sermorelin, and lipotropic injections are not FDA-approved for weight loss in any population. None have published Phase 2 or Phase 3 human weight-loss randomized controlled trial data in PubMed.
• Tesamorelin (Egrifta SV) is FDA-approved — but only for excess abdominal fat in HIV-associated lipodystrophy. Not for general weight loss.
• Foundayo (orforglipron) is FDA-approved for chronic weight management as of April 2026 — but it is not a peptide. It is a non-peptide small-molecule oral GLP-1 receptor agonist.
• If a clinic cannot name the specific active pharmaceutical ingredient in your “peptide therapy” program, that is a meaningful red flag.

Frequently asked questions

Related research

• Best oral peptides for weight loss: evidence vs. hype (2026) — narrower scope on the oral-only cluster; covers Rybelsus, Foundayo, and why every other oral peptide fails the evidence test
• Compounded tirzepatide vs. compounded semaglutide — dose schedule, storage, additives (B12, NAD+), regulatory status post-February 2025, and cost comparison
• GLP-1 shot beginner guide — how subcutaneous injection works, what to expect at each dose step, side effects in plain language, and how to get started
• Wegovy alternatives for weight management — when Wegovy is unavailable or unaffordable, what the FDA-approved alternatives are and how they compare
• Weight loss injections guide — every FDA-approved injectable in technical detail: trial data, dose ladders, safety profile, and prescriber decision framework
• Foundayo vs. Wegovy vs. Zepbound comparison — head-to-head with the published trial data and the oral-vs-injectable decision framework
• Full GLP-1 medication list 2026 — every FDA-approved GLP-1 with brand, manufacturer, indication, and DailyMed SetID links

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. “Peptides for weight loss” is a YMYL (Your Money or Your Life) topic. Every regulatory claim in this article is anchored to a primary source (DailyMed, PubMed, or FDA enforcement databases) and should be independently verified by your prescriber. Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or compounding pharmacy.